Published on 3 Nov 2023 on GuruFocus.com via Yahoo Finance
10x Genomics Inc (TXG) Reports 17% Revenue Increase in Q3 2023
10x Genomics Inc (NASDAQ:TXG) reported a 17% increase in Q3 2023 revenue, driven by Xenium momentum.The company's operating loss widened to $94.8 million from $40.0 million in the same period last year.10x Genomics Inc (NASDAQ:TXG) raised its full-year 2023 revenue guidance to a range of $610 million to $625 million.Net loss for the quarter was $93.0 million, compared to a net loss of $41.9 million in Q3 2022.
Warning! GuruFocus has detected 4 Warning Signs with TXG.
On November 2, 2023, 10x Genomics Inc (NASDAQ:TXG), a leader in single cell and spatial biology, reported its financial results for the third quarter ended September 30, 2023. The company saw a 17% increase in revenue, reaching $153.6 million, up from $131.1 million in the corresponding period of 2022. This growth was primarily driven by the momentum of the company's Xenium gene panel strategy.